Retatrutide for Hashimoto's (what you need to know)

Key wellness / self-care / productivity takeaways (from the subtitles)

• Understand thyroid lab changes on GLP-1s as “med math” shifts, not necessarily thyroid damage

  • Wegovy/retatrutide may change how levothyroxine is handled in the body (pharmacokinetics), so labs can shift even if the thyroid gland itself isn’t worsening.
  • Many clinicians don’t monitor closely enough to catch these shifts—especially if only TSH is checked annually.

• Track the right thyroid markers (not just TSH)

  • Recommended “full picture” labs mentioned:
    • Free T4
    • TSH
    • Free T3
    • TPO antibodies
    • Thyroglobulin antibodies
    • Inflammatory markers
    • Reverse T3 (when clinically warranted)

• Recognize the “3 pharmacokinetic pathways” that can shift thyroid labs during rapid weight loss

  1. Absorption
     • Levothyroxine is sensitive to food intake, gut conditions, and other meds.
     • Rapid appetite/weight changes can alter the gut environment → changed absorption.
  2. Distribution
     • As the lean-to-fat ratio changes quickly, overall thyroid hormone requirements can shift.
  3. HPA response (hypothalamic-pituitary-thyroid axis)
     • A calorie deficit can act like a stress signal, prompting the body to dial back thyroid output to conserve energy.

• Don’t chase one autoimmune metric—use symptom + lab correlation

  • Some patients report improvements in:
    • TPO antibodies
    • Inflammatory markers
    • Energy, brain fog, joint comfort, flare frequency
  • Caution: the speaker says it’s not proven that tirzepatide/retatrutide directly “treats” autoimmune disease—improvements may be secondary to fat loss and reduced inflammation.
  • Strategy: track both (antibodies + how you feel), because they can move together or at different rates.

• Why retatrutide may shift labs faster than tirzepatide (mechanism difference)

  • Tirzepatide = dual agonist (GLP-1 + GIP)
  • Retatrutide = triple agonist (GLP-1 + GIP + glucagon)
  • Glucagon effect (as described):
    • Promotes energy mobilization, increased hepatic glucose output, and fat breakdown.
  • Practical implication: faster/more aggressive fat loss may require earlier and more frequent reassessment of levothyroxine dosing.

• Prevention/optimization steps (before starting retatrutide)

  • Get a true baseline before weight loss accelerates
    • Without a baseline, it’s harder to tell what changed and how much.
  • Sequence changes—don’t start too many variables at once
    • The clinic tries to avoid stacking retatrutide changes alongside multiple other protocol changes simultaneously to separate effects.

• Whole-person “root cause” approach for Hashimoto’s (clinic model described)

  • Functional medicine + medical oversight, aiming at multiple system drivers:
    • Gut health (microbiome/immune interactions)
    • Intestinal permeability (“leaky gut”)
    • Nutritional deficiencies
    • Dietary triggers (examples: gluten and other inflammatory inputs)
    • Nervous system regulation / stress
      • Chronic stress → cortisol dysregulation → immune/inflammatory dysregulation
  • “Advanced tools” mentioned (as part of their protocols):
    • Low-dose naltrexone (LDN) for immune/inflammation modulation
    • BPC 157 and KPV (experimental models; gut repair/inflammation signaling)
    • Thymosin alpha-1 to modulate immune function (T-cell / innate immunity)

• Program structure described (if relevant to someone’s productivity/health plan planning)

  • Comprehensive blood panel reviewed by a functional medicine specialist
  • Month 1 baseline labs, then retesting several times (often quarterly)
  • Monthly visits
  • Targeted supplements adjusted based on lab movement
  • 12-month timeline framed as necessary for rebuilding dysregulated systems

---

Presenters / sources

• Dr. Jones, DC (speaker; leads a nationwide GLP-1 and metabolic clinic)
• Dr. Allen (functional medicine specialist mentioned as reviewing comprehensive blood work)
• Clinic/team references: “our team,” “my medical team” / “patient educators” (no additional named individuals in the subtitles)